Literature DB >> 17140608

Atomoxetine produces changes in cortico-basal thalamic loop circuits: assessed by phMRI BOLD contrast.

Neil Easton1, Fiona Marshall, Kevin Fone, Charles Marsden.   

Abstract

Atomoxetine is a selective noradrenaline reuptake inhibitor used in the treatment of attention deficit hyperactivity disorder (ADHD) which has not yet been assessed using pharmacological neuroimaging for its effects on rat brain activity. The pharmacological magnetic resonance imaging (phMRI) blood oxygenation level dependent (BOLD) response was determined in rat brain regions following administration of atomoxetine. Rats were individually placed into a 2.35T Bruker magnet for 60min to achieve basal recording of changes in signal intensity. Either saline (n=9) or atomoxetine hydrochloride (2mg/kg; i.p.; n=10) was then administered and recording continued for a further 90min. Data were analysed for BOLD random effects using statistical parametric maps and time course analysis. The main changes observed were widespread negative BOLD responses in the caudate putamen and changes in brain regions associated with the cortico-basal thalamic loop circuits. BOLD changes in the basal ganglia help explain its efficacy in reducing hyperactivity observed in ADHD patients. Although positive BOLD changes in the prefrontal cortex were limited to the ventral orbital cortex this is an area associated with behavioral control and may be of relevance to the use of the drug in ADHD.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17140608     DOI: 10.1016/j.neuropharm.2006.09.024

Source DB:  PubMed          Journal:  Neuropharmacology        ISSN: 0028-3908            Impact factor:   5.250


  11 in total

Review 1.  Computational models of neuronal biophysics and the characterization of potential neuropharmacological targets.

Authors:  Michele Ferrante; Kim T Blackwell; Michele Migliore; Giorgio A Ascoli
Journal:  Curr Med Chem       Date:  2008       Impact factor: 4.530

2.  Peculiar response to methylphenidate in adolescent compared to adult rats: a phMRI study.

Authors:  Rossella Canese; Walter Adriani; Eva M Marco; Francesco De Pasquale; Paola Lorenzini; Nicoletta De Luca; Fulvia Fabi; Franca Podo; Giovanni Laviola
Journal:  Psychopharmacology (Berl)       Date:  2008-11-08       Impact factor: 4.530

3.  Haplotype polymorphism in the alpha-2B-adrenergic receptor gene influences response inhibition in a large Chinese sample.

Authors:  Xuemei Lei; Chuansheng Chen; Qinghua He; Robert Moyzis; Gui Xue; Chunhui Chen; Zhongyu Cao; Jin Li; He Li; Bi Zhu; Mingxia Zhang; Jun Li; Qi Dong
Journal:  Neuropsychopharmacology       Date:  2012-01-04       Impact factor: 7.853

4.  Prefrontal and monoaminergic contributions to stop-signal task performance in rats.

Authors:  Andrea Bari; Adam C Mar; David E Theobald; Sophie A Elands; Kelechi C N A Oganya; Dawn M Eagle; Trevor W Robbins
Journal:  J Neurosci       Date:  2011-06-22       Impact factor: 6.167

Review 5.  Cognitive neuroscience of Attention Deficit Hyperactivity Disorder: current status and working hypotheses.

Authors:  Chandan J Vaidya; Melanie Stollstorff
Journal:  Dev Disabil Res Rev       Date:  2008

6.  Performance on a strategy set shifting task during adolescence in a genetic model of attention deficit/hyperactivity disorder: methylphenidate vs. atomoxetine treatments.

Authors:  Roxann C Harvey; Chloe J Jordan; David H Tassin; Kayla R Moody; Linda P Dwoskin; Kathleen M Kantak
Journal:  Behav Brain Res       Date:  2013-01-31       Impact factor: 3.332

7.  Detection of visual activation in the rat brain using 2-deoxy-2-[(18)F]fluoro-D: -glucose and statistical parametric mapping (SPM).

Authors:  M L Soto-Montenegro; J J Vaquero; J Pascau; J D Gispert; P García-Barreno; M Desco
Journal:  Mol Imaging Biol       Date:  2008-11-27       Impact factor: 3.488

8.  Differential effects of the D- and L- isomers of amphetamine on pharmacological MRI BOLD contrast in the rat.

Authors:  Neil Easton; Fiona Marshall; Kevin C F Fone; Charles A Marsden
Journal:  Psychopharmacology (Berl)       Date:  2007-03-27       Impact factor: 4.415

9.  Targeting impulsivity in Parkinson's disease using atomoxetine.

Authors:  Angie A Kehagia; Charlotte R Housden; Ralf Regenthal; Roger A Barker; Ulrich Müller; James Rowe; Barbara J Sahakian; Trevor W Robbins
Journal:  Brain       Date:  2014-06-03       Impact factor: 13.501

10.  Predictors of the Pressor Response to the Norepinephrine Transporter Inhibitor, Atomoxetine, in Neurogenic Orthostatic Hypotension.

Authors:  Cyndya A Shibao; Jose-Alberto Palma; Jorge E Celedonio; Jose Martinez; Horacio Kaufmann; Italo Biaggioni
Journal:  Hypertension       Date:  2021-06-28       Impact factor: 9.897

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.